Associated Genetic Biomarkers
ASS1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ASS1 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with ASS1 status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are ASS1 Deficiency and ASS1 Loss .
Pegargiminase, atezolizumab, carboplatin, and pemetrexed are the most frequent therapies in trials with ASS1 as an inclusion criteria .
Significance of ASS1 in Diseases
Non-Small Cell Lung Carcinoma +
ASS1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ASS1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
Pegargiminase, atezolizumab, and carboplatin are the most frequent therapies in non-small cell lung carcinoma trials with ASS1 alterations as inclusion criteria .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.